Interindividual Variability in Nicotine Metabolism: C-Oxidation and Glucuronidation
- 1 January 2005
- journal article
- review article
- Published by Japanese Society for the Study of Xenobiotics in Drug Metabolism and Pharmacokinetics
- Vol. 20 (4) , 227-235
Abstract
Nicotine has roles in the addiction to smoking, replacement therapy for smoking cessation, as a potential medication for several diseases such as Parkinson's disease, Alzheimer's disease, and ulcerative colitis. The absorbed nicotine is rapidly and extensively metabolized and eliminated to urine. A major pathway of nicotine metabolism is C-oxidation to cotinine, which is catalyzed by CYP2A6 in human livers. Cotinine is subsequently metabolized to trans-3'-hydroxycotinine by CYP2A6. Nicotine and cotinine are glucuronidated to N-glucuronides mainly by UGT1A4 and partly by UGT1A9. Trans-3'-hydroxycotinine is glucuronidated to O-glucuronide mainly by UGT2B7 and partly by UGT1A9. Approximately 90% of the total nicotine uptake is eliminated as these metabolites and nicotine itself. The nicotine metabolism is an important determinant of the clearance of nicotine. Recently, advances in the understanding of the interindividual variability in nicotine metabolism have been made. There are substantial data suggesting that the large interindividual differences in cotinine formation are associated with genetic polymorphisms of the CYP2A6 gene. Interethnic differences have also been observed in the cotinine formation and the allele frequencies of the CYP2A6 alleles. Since the genetic polymorphisms of the CYP2A6 gene have a major impact on nicotine clearance, its relationships with smoking behavior or the risk of lung cancer have been suggested. The metabolic pathways of the glucuronidation of nicotine, cotinine, and trans-3'-hydroxycotinine in humans would be one of the causal factors for the interindividual differences in nicotine metabolism. This review mainly summarizes recent results from our studies.Keywords
This publication has 44 references indexed in Scilit:
- An in Vivo Pilot Study Characterizing the New CYP2A6*7, *8, and *10 AllelesBiochemical and Biophysical Research Communications, 2002
- CYP2A6*6, a Novel Polymorphism in Cytochrome P450 2A6, Has a Single Amino Acid Substitution (R128Q) That Inactivates Enzymatic ActivityJournal of Biological Chemistry, 2001
- Duplications and Defects in theCYP2A6Gene: Identification, Genotyping, and In Vivo Effects on SmokingMolecular Pharmacology, 2000
- Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humansClinical Pharmacology & Therapeutics, 2000
- Characterization of Multiple Products of Cytochrome P450 2A6-Catalyzed Cotinine MetabolismChemical Research in Toxicology, 1999
- Deficient C-oxidation of nicotine*Clinical Pharmacology & Therapeutics, 1995
- Poor metabolisers of nicotine and CYP2D6 polymorphismThe Lancet, 1994
- Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N'-oxideChemical Research in Toxicology, 1992
- Southwestern Internal Medicine Conference: Cigarette Smoking and Lung DiseaseThe American Journal of the Medical Sciences, 1986
- Cigarette Smoking: A Dependence on High-Nicotine BoliDrug Metabolism Reviews, 1978